Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Oncoimmunology|July 25, 2014
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapseTakayuki Yoshimoto, Izuru Mizoguchi, Seiichiro Katagiri, et al.International Journal of Hematology|May 7, 2003
Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature reviewKeiko Ando, Takashi Shimamoto, Tetsuzo Tauchi, et al.International Journal of Molecular Medicine|October 8, 2005
Marked telomere fluctuation of leukocytes during graft-versus-host disease in allogeneic stem cell transplantationGoro Sashida, Junko H Ohyashiki, Naoshi Kubota, et al.International Journal of Hematology|February 16, 2017
Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitorsMichiyo Asano, Tomohiro Umezu, Seiichiro Katagiri, et al.Leukemia Research|April 7, 2011
Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosisXiaochun Zhang, Takeshi Inukai, Koshi Akahane, et al.International Journal of Hematology|February 2, 2015
A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysisKenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, et al.The Journal of Biological Chemistry|November 29, 2002
A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cellsNorio Komatsu, Tomoko Watanabe, Mie Uchida, et al.International Journal of Hematology|December 28, 2025
Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in JapanHirotaka Matsui, Jun Takizawa, Kensuke Kojima, et al.International Journal of Hematology|October 28, 2008
Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSHMasahiro Kizaki, Shinichiro Okamoto, Tetsuzo Tauchi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 4, 2003
[Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders]Tomotaka Iguchi, Jiroh Nishimaki, Ken Kawakubo, et al.Pageof 8